<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1707233874
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL-LIPURO 0.5% EMULSION FOR Inj./Infusion 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Emulsion for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        62.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="B. BRAUN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            B. BRAUN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 971]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Medical Supplies And Services Co Ltd (Mediserv)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            B. BRAUN
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AX10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Propofol-Lipuro belongs to a group of medicines called general anaesthetics. General anaesthetics are used to cause unconsciousness (sleep) so that surgical operations or other procedures can be performed. They can also be used to sedate you (so that you are sleepy but not completely asleep).</p><p>Propofol is used to<br />- induce general anaesthesia in adults and children &gt; 1 month<br />- sedate patients &gt; 16 years of age during diagnostic and surgical procedures for a short time, alone or in<br />combination with local or regional anaesthesia<br />- induce sedation in adults and children &gt; 1 month during diagnostic and surgical procedures.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Special care has to be taken<br />- if you have a disorder in which your body does not handle fat properly,<br />- if you have any other health problems which require much caution in the use of fat emulsions,<br />- if your blood volume is too low (hypovolaemia),<br />- if you are very weak (debilitated) or have heart, kidney or liver problems,<br />- if you have high pressure within in the skull,<br />- if you have problems with your breathing,<br />- if you have epilepsy,<br />- if you are undergoing some procedures where spontaneous movements are particularly undesirable.</p><p>Please tell your doctor if you have one of these diseases or conditions.<br />If you are receiving other lipids by a drip into your vein at the same time your doctor will pay attention to your total daily fat intake.<br />Propofol will be administered to you by a physician trained in anaesthesia or intensive care. You will be constantly monitored during anaesthesia and waking-up time.<br />If you experience signs of the so called &quot;epropofol infusion syndrome&quot;&nbsp;(for a detailed list of the symptoms see<br />section 4 &quot;Possible side effects&#39;, a doctor must be called if the following happen) your doctor will decrease the dosage of propofol or will switch to an alternative drug.<br />Please see also section &quot;Driving and using machines&quot;&nbsp;for precautions to be taken after the use of propfol.<br />The use of Propofol-Lipuro 5 mg/ml is not recommended in newborn infants</p><p><strong>Other medicines and Propofol-Lipuro</strong><br />Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.<br />Propofol has effectively been used with different regional anaesthesia techniques that only numb a part of<br />your body (epidural and spinal anaesthesia).<br />Additionally, safe use has been demonstrated in combination with<br />- drugs you receive before surgery<br />- other medicines like muscle relaxing drugs<br />- anaesthetic drugs that can be inhaled<br />- pain killers.<br />However your physician may give you lower doses of propofol if general anaesthesia or sedation is needed as a supplement to regional anaesthesia techniques.</p><p><strong>Propofol-Lipuro and alcohol</strong><br />Your doctor will advise you on the consumption of alcohol before and after the use of Propofol-Lipuro.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Propofol-Lipuro should not be used during pregnancy unless it is definitely needed. It crosses the placenta and may depress the vital functions of the newborn.<br />However, propofol may be used during an induced abortion.</p><p>If you are breast-feeding your child you should stop nursing and discard breast milk for 24 hours after you have received Propofol-Lipuro. Studies in breast-feeding women showed that propofol is excreted in small amounts into the milk.</p><p><strong>Driving and using machines</strong><br />You should not drive or operate machinery for a while after you have an injection or infusion of Propofol-<br />Lipuro..<br />Your doctor will advise you<br />- if you should be accompanied when you are leaving.<br />- when you can drive and use machinery again.<br />- on the use of other tranquillizing drugs (e.g. tranquillizers, strong pain killers, alcohol).</p><p><strong>Propofol-Lipuro contains sodium and soya-bean oil</strong><br />This medicinal product contains less than 1 mmol (23 mg) sodium in 20 ml, that is, it is essentially&#39; sodium<br />fre&#39;.<br />Propofol-Lipuro contains soya-bean oil. If you are allergic to peanut or soya, do not use this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Propofol-Lipuro will only be given by anaesthetists or by specially trained doctors in an intensive care unit.</p><p><strong>Dosage</strong><br />The dose you are given will vary depending on your age, body weight and physical condition. The doctor will give the correct dose to start anaesthesia or to achieve the required level of sedation, by carefully watching your responses and vital signs (pulse, blood pressure, breathing, etc). The doctor will also observe the limits of the time of application, if necessary.<br />Propofol-Lipuro will usually be given by injection when used to induce general anaesthesia. When used as a sedative it will usually be administered slowly and continuously by infusion using an appropriate apparatus.<br />When given as an infusion it will be diluted in advance.<br />Propofol-Lipuro will only be given for a maximum of 1 hour.</p><p><strong>Method of administration</strong><br />You will receive Propofol-Lipuro by intravenous injection or infusion, that is, through a needle or small tube<br />placed in one of your veins.<br />Your circulation and breathing will be constantly monitored while you are being given the injection or the infusion.</p><p><strong>If you received more Propofol-Lipuro than you should</strong><br />It is unlikely that this occurs because the doses you receive are very carefully controlled.<br />Yet if you accidentally got an overdose, this could lead to depression of heart function and breathing. In this<br />case your doctor will employ any necessary treatment immediately.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />A doctor must be called immediately if the following happen Common (may affect up to 1 in 10 people):<br />- Low blood pressure that might occasionally need infusion of fluids and reduction of the speed of<br />administration of propofol.<br />- Too low heartbeat that might be serious in rare cases.<br />Rare (may affect up to 1 in 1,000 people):<br />- Convulsions like in epilepsy</p><p>Very rare: (may affect up to 1 in 10,000 people)<br />- Allergic reactions including swelling of the face, tongue or throat, wheezing breath, skin redness and<br />low blood pressure<br />- There have been cases of unconsciousness occurring after operations. You will therefore be carefully<br />observed during the waking-up time.<br />- Water on the lungs (lung oedema) after administration of propofol<br />- Inflammation of the pancreas</p><p>Not known (frequency cannot be estimated from the available data):<br />- There have been reports of isolated cases of severe adverse reactions presenting as a combination of the following symptoms: breakdown of muscle tissue, accumulation of acidic (sour) substances in the blood, abnormally high blood potassium level, high blood fat levels, abnormalities in the electrocardiogram (Brugada-type ECG), liver enlargement, irregular heart-beat, kidney failure and heart failure. This has been called the &quot;propofol infusion syndrome&quot;. Some of the affected patients eventually died. These effects have only been seen in patients in intensive care with doses higher than 4 mg of<br />propofol per kg body weight per hour. See also section 2, &quot;Warnings and precautions&quot;.</p><p><strong>Other side effects are:</strong></p><p>Very common (affects more than 1 treated patient of 10):<br />- Pain at the injection site occurring during the first injection. The pain may be reduced by injecting<br />propofol into larger veins of the forearm. Injection of lidocaine (a local anaesthetic) and propofol at the<br />same time also helps to reduce the pain at the injection site.</p><p>Common (may affect up to 1 in 10 people):<br />- Short interruption of breathing<br />- Headache during the time of recovery<br />- Sickness or vomiting during the time of recovery</p><p>Uncommon (may affect up to 1 in 100 people):<br />&nbsp;Blood clots in veins or inflammation of veins</p><p>Very rare (may affect up to 1 in 10,000 people)<br />- Loss of sexual control during the time of recovery<br />- Abnormal colour of urine after longer lasting administration of propofol<br />- Cases of fever after an operation</p><p>Not known (frequency cannot be estimated from the available data):<br />- Involuntary movements<br />- Abnormally good mood<br />- Drug abuse<br />- Failure of the heart<br />- Breakdown of muscle tissue has been reported very rarely in cases where propofol has been given at greater doses than recommanded for sedation in intensive care units</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in this leaflet.</p><p><strong>You can also report side effects directly via<br />National Pharmacovigilance &amp; Drug Safety Center (NPC)<br />&ndash; Fax: +966-11-205-7662<br />&ndash; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340<br />&ndash; Toll free phone: 8002490000<br />&ndash; E-mail: npc.drug@sfda.gov.sa<br />&ndash; Website: www.sfda.gov.sa/npc</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month.</p><p>Keep the ampoules in the outer carton in order to protect from light..<br />Do not store above 25<sup>0</sup>C. Do not freeze.</p><p>Propofol-Lipuro must be used immediately after opening/dilution.</p><p>Do not use Propofol-Lipuro if two separate layers can be seen after shaking the ampoule or if it is not milkywhite.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>- The active substance is propofol.</strong><br />Each millilitre of Propofol-Lipuro 5 mg/ml contains 5 mg of propofol.<br />1 ampoule of 20 ml contains 100 mg propofol.</p><p>&nbsp;</p><p>- <strong>The other ingredients are:</strong><br />Soya-bean oil, refined,<br />Medium-chain triglycerides,<br />Egg lecithin,<br />Glycerol,<br />Sodium oleate,<br />Water for injections.N</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                It is an emulsion for injection or infusion.
It is a milky-white oil-in water emulsion.

It comes in glass ampoules of 20 millilitres, available in packs of 5 ampoules .

Not all pack sizes may be marketeds.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>B. Braun Melsungen AG<br />Carl-Braun-Str.1&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; Postal address:<br />34212 Melsungen, Germany&nbsp; &nbsp; &nbsp; &nbsp; 34209 Melsungen, Germany<br />Phone: +49/5661/71-0<br />Fax: +49/5661/71-4567</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي بروبوفول-ليبورو إلى مجموعة من الأدوية يُطلق عليها أدوية التخدير العام. تُستخدم أدوية التخدير العام في إحداث فقدان الوعي (النوم) حتى يمكن القيام بالعمليات الجراحية، أو الإجراءات الأخرى. ويمكن أن تُستخدم أيضًا في تهدئتك (بحيث تشعر بالنعاس ولكن لا تصبح نائمًا بشكل كامل).</p><p>&nbsp;</p><p dir="RTL">يستخدم بروبوفول لعمل الآتي</p><p dir="RTL">●&nbsp;&nbsp;تحفيز التخدير العام لدى البالغين والأطفال ممن تزيد أعمارهم عن شهر واحد</p><p dir="RTL">●&nbsp;&nbsp;تهدئة المرضى الأكبر من 16 عامًا أثناء عمل الإجراءات التشخيصية والجراحية لفترة قصيرة، سواءً تم استخدامه بمفرده أو بالتزامن مع استخدام مخدر موضعي أو مخدر طرفي</p><p dir="RTL">●&nbsp;&nbsp;تحفيز التهدئة لدى البالغين والأطفال ممن تزيد أعمارهم عن شهر واحد أثناء عمل الإجراءات التشخيصية والجراحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بروبوفول</strong><strong>-</strong><strong>ليبورو</strong></p><p dir="RTL">●&nbsp; إذا كنت مصابًا بالحساسية (فرط الحساسية) تجاه البروبوفول، أو الصويا، أو الفول السوداني، أو أي من مكونات هذا الدواء (المذكورة في القسم&nbsp;6).</p><p dir="RTL">● لمداومة التخدير العام أو التهدئة أثناء عمل الإجراءات التشخيصية والجراحية لدى الأطفال</p><p dir="RTL">●&nbsp; للتهدئة أثناء تلقي الرعاية في العناية المركزة.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">سيتم توخي الحذر بشكل خاص عند استخدام الدواء</p><ul dir="rtl"><li>إذا كان لديك اضطراب يمنع جسمك من التعامل مع الدهون بشكل صحيح،</li><li>إذا كنت تعاني من أي مشاكل صحية أخرى تتطلب الحذر في استخدام المستحلبات الدهنية،</li><li>إذا كان حجم دمك قليلًا للغاية (نقص حجم الدم)،</li><li>&nbsp;ذا كنت ضعيفًا للغاية (تعاني من الوهن) أو تعاني من مشكلات في القلب أو الكلى أو الكبد،</li><li>إذا كنت تعاني من ارتفاع الضغط داخل الجمجمة،</li><li>إذا كنت تعاني من مشكلات في التنفس،</li><li>إذا كنت تعاني من الصرع،</li><li>إذا كنت تخضع لبعض الإجراءات التي تتطلب بشكل خاص ألا تقوم بحركات تلقائية.</li></ul><p dir="RTL">يرجى أن تخبر طبيبك إذا كنت تعاني من أيٍ من هذه الأمراض أو الحالات.</p><p dir="RTL">إذا كنت تتلقى دهونًا أخرى في نفس الوقت عن طريق التقطير في وريدك، فسينتبه طبيبك إلى إجمالي حصة الدهون التي تتناولها يوميًا.</p><p dir="RTL">سيتم إعطاؤك بروبوفول بواسطة طبيب مدرَّب في التخدير أو العناية المركزة. ستتم مراقبتك باستمرار أثناء التخدير وفي وقت الإفاقة.</p><p dir="RTL">إذا أصبت بالعلامات الخاصة بما يطلق عليه &quot;متلازمة تسريب البروبوفول&quot; (للاطلاع على قائمة مفصلة بالأعراض انظر القسم&nbsp;4 &quot;الآثار الجانبية المحتملة&quot;، يجب استدعاء طبيب إذا حدث ما يلي) فسيقوم طبيبك بتخفيض جرعة البروبوفول أو سينتقل إلى استخدام عقار بديل.</p><p dir="RTL">يُرجى الاطلاع أيضًا على قسم &quot;القيادة واستخدام الآلات&quot; للاطلاع على الاحتياطات التي ينبغي اتخاذها بعد استخدام بروبوفول.</p><p dir="RTL">يوصى بعدم استخدام بروبوفول-ليبورو 5&nbsp;مجم/مل مع الأطفال حديثي الولادة</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى و بروبوفول</strong><strong>-</strong><strong>ليبورو</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتلقى حاليًا، أو تلقيت مؤخرًا، أو قد تتلقى أي أدوية أخرى.</p><p>تم استخدام بروبوفول بفاعلية مع أساليب التخدير الطرفية المختلفة، والتي تؤدي إلى تنميل جزء من جسمك فقط (التخدير فوق الجافية والتخدير النخاعي).</p><p dir="RTL">بالإضافة إلى ذلك، ثبت الاستخدام الآمن عند استعمال هذا الدواء بالتزامن مع</p><ul dir="rtl"><li>الأدوية التي تتلقاها قبل الجراحة</li><li>الأدوية الأخرى مثل أدوية إرخاء العضلات</li><li>أدوية التخدير التي يمكن استنشاقها</li><li>مسكنات الألم.</li></ul><p>ومع ذلك، فقد يعطيك طبيبك جرعات أقل من بروبوفول إذا كانت هناك حاجة للتخدير العام، أو التهدئة، كدعم لأساليب التخدير الطرفية.</p><p>&nbsp;</p><p dir="RTL"><strong>بروبوفول</strong><strong>-</strong><strong>ليبورو والكحول</strong></p><p dir="RTL">سينصحك طبيبك بشأن تناول الكحوليات قبل وبعد استخدام بروبوفول-ليبورو.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو كنتِ تعتقدين أنك قد تكونين حاملًا أو كنتِ تخططين لإنجاب طفل، فاستشيري طبيبك أو الصيدلي قبل أخذ هذا الدواء.</p><p dir="RTL">ينبغي عدم استخدام بروبوفول-ليبورو أثناء الحمل ما لم تكن هناك حاجة حتمية لذلك. فهو يعبر المشيمة وقد يتسبب في تثبيط الوظائف الحيوية لدى حديثي الولادة.</p><p dir="RTL">لكن يمكن استخدام بروبوفول أُثناء إجراء الإجهاض المحرَّض.</p><p dir="RTL">إذا كنتِ ترضعين طفلكِ رضاعة طبيعية، ينبغي أن تتوقفي عن الرضاعة وتتخلصي من حليب الثدي طوال 24&nbsp;ساعة بعد تلقيك بروبوفول-ليبورو. أظهرت الدراسات التي أجريت على النساء اللاتي يرضعن رضاعة طبيعية أن بروبوفول يُفرز في حليب الثدي بكميات صغيرة.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا تقم بالقيادة، أو استخدام الآلات لفترة بعد تلقي الحقن، أو التسريب الوريدي من بروبوفول-ليبورو.</p><p dir="RTL">سيقوم طبيبك بتقديم النصيحة لك</p><p dir="RTL">● إذا كان ينبغي أن يصطحبك أحد الأشخاص عند مغادرتك مكان العلاج.</p><p dir="RTL">● بالوقت الذي يمكنك أن تقوم فيه بالقيادة واستخدام الآلات مرة أخرى.</p><p dir="RTL">● بشأن استخدام العقاقير المهدئة الأخرى (مثل المهدئات، مسكنات الألم القوية، الكحول).</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي بروبوفول</strong><strong>-</strong><strong>ليبورو على الصوديوم وزيت فول الصويا</strong></p><p dir="RTL">يحتوي هذا المنتج الدوائي على أقل من 1&nbsp;ميلي مول (23&nbsp;مجم) من الصوديوم لكل 20&nbsp;مل، أي إنه يُعد &quot;خاليًا من الصوديوم&quot;.</p><p dir="RTL">يحتوي بروبوفول-ليبورو على زيت فول الصويا. إذا كنت مصابًا بالحساسية تجاه الفول السوداني أو الصويا، فلا تستخدم هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاء بروبوفول-ليبورو بواسطة أخصائي التخدير، أو أطباء تم تدريبهم بشكل خاص في وحدة العناية المركزة.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">ستختلف الجرعة التي تتناولها بناءً على عمرك، ووزن جسمك، وحالتك البدنية. سيقوم الطبيب بإعطاء الجرعة الصحيحة لبدء التخدير، أو للوصول إلى المستوى المطلوب من التهدئة من خلال مراقبة استجاباتك، والعلامات الحيوية بدقة (النبض، ضغط الدم، التنفس، إلخ). إذا كان ذلك ضروريًا، فسيقوم الطبيب أيضًا بملاحظة حدود وقت الإعطاء.</p><p dir="RTL">عادةً ما سيتم إعطاء بروبوفول-ليبورو عن طريق الحقن، عند استخدامه لتحفيز التخدير العام. عند استخدامه كمهدئ، فغالبًا ما سيُعطى الدواء ببطء واستمرار عن طريق التسريب الوريدي، وذلك باستخدام الجهاز المناسب. عندما يُعطى عن طريق التسريب الوريدي، فسيتم تخفيفه مسبقا.</p><p dir="RTL">سيتم إعطاء بروبوفول-ليبورو لمدة ساعة واحدة كحد أقصى.</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">ستتلقى بروبوفول-ليبورو عن طريق الحقن أو التسريب الوريدي، أي من خلال إبرة أو أنبوب صغير يتم وضعه في أحد أوردتك.</p><p dir="RTL">ستتم مراقبة دورتك الدموية وتنفسك بشكل مستمر، أثناء إعطائك الحقن أو التسريب الوريدي.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تلقيت كمية من بروبوفول</strong><strong>-</strong><strong>ليبورو أكثر مما ينبغي</strong></p><p dir="RTL">من غير المرجح أن يحدث هذا لأن الجرعات التي تتلقاها يتم التحكم فيها بعناية شديدة.</p><p dir="RTL">ومع ذلك، إذا تلقيت جرعة زائدة عن طريق الخطأ، فقد يؤدي هذا إلى قصور في وظائف القلب والتنفس. في هذه الحالة سيقوم طبيبك بتقديم أي علاج ضروري على الفور.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا المنتج، فاطرحها على طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>يجب استدعاء طبيب على الفور إذا حدث أي من الأعراض التالية</strong></p><p dir="RTL"><u>شائعة (قد تصيب ما يصل إلى 1 من كل 10&nbsp;أشخاص):</u></p><p dir="RTL">● انخفاض ضغط الدم الذي قد يحتاج أحيانًا إلى تسريب السوائل، وتخفيض سرعة إعطاء بروبوفول.</p><p dir="RTL">● بطء معدل ضربات القلب بدرجة كبيرة، والذي قد يكون خطيرا في حالات نادرة.</p><p>&nbsp;</p><p dir="RTL">ن<u>ادرة (قد تصيب ما يصل إلى 1 من كل 1,000&nbsp;شخص):</u></p><p dir="RTL">● تشنجات تشبه الصرع</p><p>&nbsp;</p><p dir="RTL"><u>نادرة جدًا (قد تصيب ما يصل إلى 1 من كل 10000 شخص)</u></p><p dir="RTL">●تفاعلات تحسسية تتضمن تورم الوجه، أو اللسان، أو الحلق، والأزيز أثناء التنفس، واحمرار الجلد، وانخفاض ضغط الدم</p><p dir="RTL">● لقد كان هناك حالات من فقدان الوعي حدثت بعد العمليات. لذلك ستتم مراقبتك بعناية خلال مرحلة الإفاقة.</p><p dir="RTL">●&nbsp; وجود ماء على رئتيك (وذمة الرئة) بعد استعمال بروبوفول</p><p dir="RTL">●&nbsp; &nbsp;التهاب البنكرياس</p><p>&nbsp;</p><p dir="RTL"><u>غير معروف (لا يمكن تقدير معدل التكرار من البيانات المتاحة):</u></p><p dir="RTL">● لقد وردت تقارير عن حالات منفردة أصيبت بتفاعلات ضارة شديدة تظهر في صورة مجموعة من الأعراض التالية: تحلل نسيج العضلات، وتراكم المواد الحمضية (اللاذعة) في الدم، وارتفاع مستويات البوتاسيوم في الدم بصورة غير طبيعية، وارتفاع مستويات الدهون في الدم، واضطرابات في مخطط كهربية القلب (اضطراب مخطط كهربية القلب الذي يُعرف باسم متلازمة بروجادا)، وتضخم الكبد، وعدم انتظام ضربات القلب، والفشل الكلوي، وفشل القلب</p><p dir="RTL">وقد سُمي هذا بـ &quot;متلازمة تسريب البروبوفول&quot;. بعض ممن أصيبوا بهذه الأعراض انتهى الأمر بوفاتهم. لوحظت هذه الآثار فقط في مرضى العناية المركزة الذين يتلقون جرعات أكبر من 4&nbsp;مجم من بروبوفول لكل كجم من وزن الجسم في ساعة. انظر أيضًا القسم&nbsp;2، &quot;تحذيرات واحتياطات&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى هي</strong><strong>:</strong></p><p dir="RTL">شائعة جدًا (تصيب أكثر من مريض واحد يتم علاجه من كل 10):</p><p dir="RTL">● ألم في موضع الحقن يحدث أُثناء إعطاء أول حقنة. يمكن تقليل الألم عن طريق حقن بروبوفول في أوردة أكبر في الساعد. ويساعد أيضًا حقن ليدوكايين (مخدر موضعي) مع بروبوفول في نفس الوقت على تقليل الألم في موضع الحقن.</p><p>&nbsp;</p><p dir="RTL">شائعة (قد تصيب ما يصل إلى 1 من كل 10&nbsp;أشخاص):</p><p dir="RTL">●&nbsp; &nbsp; &nbsp;انقطاع قصير في التنفس</p><p dir="RTL">●&nbsp; &nbsp; &nbsp;الصداع خلال فترة الإفاقة</p><p dir="RTL">●&nbsp; &nbsp; الغثيان أو التقيؤ خلال فترة الإفاقة</p><p>&nbsp;</p><p dir="RTL">غير شائعة (قد تصيب ما يصل إلى شخص واحد من كل 100&nbsp;شخص):</p><p dir="RTL">● تكون جلطات دموية في الأوردة أو التهاب الأوردة</p><p>&nbsp;</p><p dir="RTL">نادرة جدًا (قد تصيب ما يصل إلى 1 من كل 10,000&nbsp;شخص):</p><p dir="RTL">●&nbsp; فقدان القدرة الجنسية خلال فترة الإفاقة</p><p dir="RTL">● لون غير طبيعي للبول بعد استعمال بروبوفول لفترة طويلة</p><p dir="RTL">●حالات الحمى بعد الخضوع لعملية</p><p>&nbsp;</p><p dir="RTL">غير معروف (لا يمكن تقدير معدل التكرار من البيانات المتاحة):</p><p dir="RTL">●&nbsp; حركات لا إرادية</p><p dir="RTL">●&nbsp; &nbsp;حالة مزاجية جيدة بشكل غير طبيعي</p><p dir="RTL">●&nbsp; &nbsp;سوء استخدام العقاقير</p><p dir="RTL">●&nbsp; &nbsp; فشل القلب</p><p dir="RTL">● لقد وردت تقارير عن حالات نادرة من تحلل نسيج العضلات عند إعطاء بروبوفول بجرعات أعلى من الموصى بها للتهدئة في وحدات العناية المركزة</p><p>&nbsp;</p><p dir="RTL">إذا عانيت من أي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي الخاص بك أو الممرضة. يتضمن هذا أي آثار جانبية غير مذكورة في هذه النشرة.</p><p dir="RTL"><strong>يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً من خلال</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية (NCP)</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفاكس: 7662-205-11-966+</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الرقم 2038222-11-966+، تحويلة: 2317-2356-2353-2354-2334-2340</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق وعلى العلبة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">احفظ الأمبولات في العلبة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">لا يُحفظ في درجة حرارة أعلى من 25 درجة مئوية. لا تقم بتجميد الدواء.</p><p dir="RTL">يجب استخدام بروبوفول-ليبورو فورًا بعد الفتح/التخفيف.</p><p dir="RTL">لا تستخدم بروبوفول-ليبورو إذا كان بإمكانك رؤية طبقتين منفصلتين بعد رج الأمبولة، أو إذا لم يكن لونه أبيض حليبي.</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو مع النفايات المنزلية. اسأل الصيدلي كيف تتخلص من أي أدوية لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتوي عليه بروبوفول</strong><strong>-</strong><strong>ليبورو</strong></p><p dir="RTL">●<u> المادة الفعالة هي بروبوفول.</u></p><p dir="RTL">يحتوي كل ميلي لتر من بروبوفول-ليبورو 5&nbsp;مجم/مل على 5&nbsp;مجم من بروبوفول.</p><p dir="RTL">تحتوي كل أمبولة سعة 20&nbsp;مل على 100&nbsp;مجم بروبوفول.</p><p>&nbsp;</p><p dir="RTL"><u>●&nbsp; المكونات الأخرى هي:</u></p><p dir="RTL">زيت فول الصويا المُكرر،</p><p dir="RTL">ثلاثي الجليسريد متوسط السلسلة،</p><p dir="RTL">ليسيثين البيض،</p><p dir="RTL">جليسيرول،</p><p dir="RTL">أوليات الصوديوم،</p><p dir="RTL">ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل بروبوفول</strong><strong>-</strong><strong>ليبورو وما هي محتويات العبوة</strong></p><p>&nbsp;</p><p dir="RTL">هو مستحلب مخصص للحقن أو التسريب الوريدي.</p><p dir="RTL">هو مستحلب من الزيت في الماء ولونه أبيض كلون الحليب.</p><p dir="RTL">متوفر في أمبولات زجاجية سعة 20 ميلي لتر، متاحة في عبوات تحتوي على 5 أمبولات.</p><p dir="RTL">قد لا تُطرح جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل تصريح التسويق والشركة المُصنّعة</strong></p><p>&nbsp;</p><p dir="RTL">B. Braun Melsungen AG</p><p dir="RTL">Carl-Braun-Stra&szlig;e 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العنوان البريدي:</p><p dir="ltr">34209 Melsungen, Germany&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 34212 Melsungen, Germany</p><p>&nbsp;</p><p dir="RTL">الهاتف: 0-71/ 5661/ 49+</p><p dir="RTL">الفاكس: 4567-71/5661/49+</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2013.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propofol-Lipuro 5 mg/ml emulsion for injection or infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml emulsion for injection or infusion contains 5 mg propofol.
1 ampoule with 20 ml contains 100 mg propofol

Excipients with known effects:
1 ml of emulsion contains
Soya-bean oil refined 50 mg
Sodium 0.03 mg

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emulsion for injection or infusion.
White milky oil-in-water emulsion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Propofol-Lipuro 5 mg/ml is a short-acting intravenous general anaesthetic indicated for</p><ul><li style="text-align: justify;">&nbsp;induction of general anaesthesia in adults and children &gt; 1 month</li><li style="text-align: justify;">induction of sedation for diagnostic and surgical procedures, in adults and children &gt; 1 month</li><li style="text-align: justify;">short term sedation for diagnostic and surgical procedures, alone or in combination with local orregional anaesthesia in adults only.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">General instructions<br />Propofol-Lipuro 5 mg/ml must only be given in hospitals or adequately equipped day therapy units by physicians trained in anaesthesia or in the care of patients in intensive care. Circulatory and respiratory functions should be constantly monitored (e.g. ECG, pulse-oxymeter) and facilities for maintenance of patent airways, artificial ventilation, and other resuscitation facilities should be immediately available at all times. For sedation during surgical or diagnostic procedures Propofol-Lipuro 5 mg/ml should not be given by the same person that carries out the surgical or diagnostic procedure.</p><p style="text-align:justify">Propofol-Lipuro 5 mg/ml is intended for use in children, adolescents and adults, especially the painsensitive ones, because of the lower pain on injection compared to higher strengths.<br />Supplementary analgesic medicinal products are generally required in addition to Propofol-Lipuro 5 mg/ml.</p><p style="text-align:justify">Posology<br />Propofol-Lipuro 5 mg/ml is given intravenously. The dosage is adjusted individually according to the<br />patient&#39;s response.</p><p style="text-align:justify">General anaesthesia in adults<br />Induction of anaesthesia:<br />For induction of anaesthesia Propofol-Lipuro 5 mg/ml should be titrated (20 . 40 mg of propofol<br />every 10 seconds) against the patient&#39;s response until the clinical signs show the onset of anaesthesia.<br />Most adult patients younger than 55 years are likely to require 1.5 to 2.5 mg of propofol per kg body<br />weight. Repeat bolus injections may be given according to clinical requirements.</p><p style="text-align:justify">In patients over this age and in patients of ASA grades III and IV, especially those with impaired cardiac<br />function, the dosage requirements will be less and the total propofol dose may be reduced to a<br />minimum of 1 mg/kg body weight. In these patients lower rates of administration should be applied<br />(approximately 4 ml of Propofol-Lipuro 5 mg/ml, corresponding to 20 mg of propofol every 10 seconds).</p><p style="text-align:justify">Induction of general anaesthesia in children over 1 month of age<br />For induction of anaesthesia Propofol-Lipuro 5 mg/ml should be slowly titrated against the patient&#39;s<br />response until the clinical signs show the onset of anaesthesia. The dosage should be adjusted according to age and/or body weight. Most patients over 8 years of age require approximately 2.5 mg of propofol<br />per kg body weight for induction of anaesthesia. In younger children, especially between the age of 1 month and 3 years, dose requirement may be higher (2.5 . 4 mg of propofol per kg body weight).</p><p style="text-align:justify">Propofol-Lipuro 5 mg/ml is contraindicated to be used for maintenance of anaesthesia (see also section 4.3)<br />For ASA III and IV patients lower doses are recommended (see also section 4.4).</p><p style="text-align:justify">&nbsp;Sedation for diagnostic and surgical procedures in adult patients<br />To provide sedation during surgical and diagnostic procedures, doses and administration rates should be adjusted according to the clinical response. Most patients will require 0.5 . 1 mg of propofol per kg body weight over 1 to 5 minutes for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol-Lipuro 5 mg/ml to the desired level, using e.g. a syringe pump. Most patients will require 1.5 . 4.5 mg of propofol per kg body weight per hour. Additional boluses of 10 . 20 mg of<br />propofol (2 . 4 ml of Propofol-Lipuro 5 mg/ml) may be given if a rapid increase of the depth of sedation is required.</p><p style="text-align:justify">In patients older than 55 years and in patients of ASA grade III and IV lower doses of Propofol-Lipuro<br />5 mg/ml may be required and the rate of administration may need to be reduced.</p><p style="text-align:justify">Induction of sedation for diagnostic and surgical procedures in children over 1 month of age<br />Doses and administration rates should be adjusted according to the required depth of sedation and the<br />clinical response. Most paediatric patients require 1 . 2 mg/kg body weight of propofol for onset of sedation.</p><p style="text-align:justify">In ASA III and IV patients lower doses may be required.</p><p style="text-align:justify">Method and duration of administration<br />�� Method of administration<br />Intravenous use<br />Propofol-Lipuro 5 mg/ml is administered intravenously undiluted by injection either or by continuous<br />infusion after dilution with glucose 50 mg/ml (5 % w/v) solution, sodium chloride 9 mg/ml (0.9 % w/v) solution.</p><p style="text-align:justify">Containers should be shaken before use.</p><p style="text-align:justify">Before use, the neck of the ampoule should be cleaned with medicinal alcohol (spray or swabs). After<br />use, tapped containers must be discarded.</p><p style="text-align:justify">If infusion sets with filters are to be used, these must be lipid-permeable.</p><p style="text-align:justify">Administration of undiluted Propofol-Lipuro 5 mg/ml</p><p style="text-align:justify">When administering Propofol-Lipuro 5 mg/ml continuously, administration rates should always be<br />controlled by appropriate apparatus, e.g a syringe pump. Any portion of Propofol-Lipuro 5 mg/ml remaining<br />after the end of administration must be discarded.</p><p style="text-align:justify">Infusion of diluted Propofol-Lipuro 5 mg/ml</p><p style="text-align:justify">For infusion of diluted Propofol-Lipuro 5 mg/ml, burettes, drop counters, syringe pumps, or volumetric<br />infusion pumps should always be used to control infusion rates and to avoid the risk of accidentally<br />uncontrolled infusion of large volumes of diluted Propofol-Lipuro 5 mg/ml.</p><p style="text-align:justify">The maximum dilution must not exceed 1 part of Propofol-Lipuro 5 mg/ml with 4 parts of glucose 50<br />mg/ml (5 % w/v) solution or sodium chloride 9 mg/ml (0.9 % w/v) solution (minimum concentration 1<br />mg propofol/ml).</p><p style="text-align:justify">For suitable diluents please refer to section 6.6.<br />The pain on initial injection may be reduced by adding lidocaine to Propofol-Lipuro 5 mg/ml: One<br />part of preservative-free lidocaine injection 10 mg/ml (1 %) may be added to 40 parts of Propofol-<br />Lipuro 5 mg/ml.</p><p style="text-align:justify">Before giving the muscle relaxants atracurium or mivacurium subsequent to Propofol-Lipuro 5 mg/ml<br />through the same intravenous line, it is recommended that the line be rinsed prior to administration.</p><p style="text-align:justify">&nbsp;Duration of administration<br />Propofol-Lipuro 5 mg/ml can be administered for a maximum period of 1 hour.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Propofol-Lipuro 5 mg/ml is contraindicated in patients with a known hypersensitivity to propofol or
any of the excipients.

Propofol-Lipuro 5 mg/ml contains soya-bean oil and should not be used in patients who are hypersensitive
to peanut or soya.

Propofol-Lipuro 5 mg/ml is contraindicated:
- for maintenance of general anaesthesia
- for maintenance of sedation for diagnostic and surgical procedures in children
- for sedation for intensive care
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Propofol should be given by those trained in anaesthesia (or, where appropriate, doctors trained in the<br />care of patients in Intensive Care).</p><p style="text-align:justify">Patients should be constantly monitored and facilities for maintenance of a patent airway, artificial<br />ventilation, oxygen enrichment and other resuscitative facilities should be readily available at all<br />times. Propofol should not be administered by the person conducting the diagnostic or surgical procedure.</p><p style="text-align:justify">The abuse of propofol, predominantly by health care professionals, has been reported. As with other<br />general anaesthetics, the administration of propofol without airway care may result in fatal respiratory<br />complications.</p><p style="text-align:justify">When propofol is administered for conscious sedation, for surgical and diagnostic procedures, patients<br />should be continually monitored for early signs of hypotension, airway obstruction and oxygen desaturation.</p><p style="text-align:justify">In case of repeated boli for induction of anaesthesia the maximum fat administration should not exceed<br />150 mg fat/kg/h which corresponds to 1.5 ml/kg/h of Propofol-Lipuro 5 mg/ml.</p><p style="text-align:justify">As with other sedative agents, when propofol is used for sedation during operative procedures, involuntary<br />patient movements may occur. During procedures requiring immobility these movements may<br />be hazardous to the operative site.</p><p style="text-align:justify">An adequate period is needed prior to discharge of the patient to ensure full recovery after use of propofol.<br />Very rarely the use of propofol may be associated with the development of a period of postoperative<br />unconsciousness, which may be accompanied by an increase in muscle tone. This may or<br />may not be preceded by a period of wakefulness. Although recovery is spontaneous, appropriate care<br />of an unconscious patient should be administered.</p><p style="text-align:justify">Propofol induced impairment is not generally detectable beyond 12 hours. The effects of propofol, the<br />procedure, concomitant medications, the age and the condition of the patient should be considered when advising patients on:<br />- The advisability of being accompanied on leaving the place of administration<br />- The timing of recommencement of skilled or hazardous tasks such as driving<br />- The use of other agents that may sedate (e.g. benzodiazepines, opiates, alcohol.)<br /><br />As with other intravenous agents, caution should be applied in patients with cardiac, respiratory, renal<br />or hepatic impairment or in hypovolaemic or debilitated patients.</p><p style="text-align:justify">Propofol clearance is blood flow dependent, therefore, concomitant medication that reduces cardiac<br />output will also reduce propofol clearance.</p><p style="text-align:justify">Propofol lacks vagolytic activity and has been associated with reports of bradycardia (occasionally<br />profound) and also asystole. The intravenous administration of an anticholinergic agent before induction<br />of anaesthesia should be considered, especially in situations where vagal tone is likely to predominate<br />or when propofol is used in conjunction with other agents likely to cause bradycardia.</p><p style="text-align:justify">When propofol is administered to an epileptic patient, there may be a risk of convulsion.</p><p style="text-align:justify">Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions<br />where lipid emulsions must be used cautiously.<br />It is recommended that blood lipid levels should be monitored if propofol is administered to patients<br />thought to be at particular risk of fat overload. Administration of propofol should be adjusted appropriately<br />if the monitoring indicates that fat is being inadequately cleared from the body. If the patient<br />is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to<br />take account of the amount of lipid infused as part of the propofol formulation; 1.0 ml of Propofol-<br />Lipuro 5 mg/ml contains 0.1 g of fat.</p><p style="text-align:justify">The use of propofol is not recommended in newborn infants as this patient population has not been<br />fully investigated. Pharmacokinetic data (see section 5.2) indicate that clearance is considerably reduced<br />in neonates and has a very high inter-individual variability. Relative overdose could occur on<br />administering doses recommended for older children and result in severe cardiovascular depression.</p><p style="text-align:justify">Advisory statements concerning Intensive Care Unit management<br />The safety and efficacy of propofol for (background) sedation in children younger than 16 years of age<br />have not been demonstrated. Although no causal relationship has been established, serious undesirable<br />effects with (background) sedation in patients younger than 16 years of age (including cases with fatal<br />outcome) have been reported during unlicensed use. In particular these effects concerned occurrence<br />of metabolic acidosis, hyperlipidemia, rhabdomyolysis and/or cardiac failure. These effects were most<br />frequently seen in children with respiratory tract infections who received dosages in excess of those<br />advised in adults for sedation in the intensive care unit.</p><p style="text-align:justify">Reports have been received of combinations of the following: Metabolic acidosis, Rhabdomyolysis,<br />Hyperkalaemia, Hepatomegaly, Renal failure, Hyperlipidaemia, Cardiac arrhythmia, Brugada-type<br />ECG (elevated ST-segment and coved T-wave) and rapidly progressive Cardiac failure usually unresponsive<br />to inotropic supportive treatment (in some cases with fatal outcome) in adults. Combinations<br />of these events have been referred to as the Propofol infusion syndrome.</p><p style="text-align:justify">The following appear to be the major risk factors for the development of these events: decreased oxygen<br />delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the<br />following pharmacological agents - vasoconstrictors, steroids, inotropes and/or propofol (usually following<br />extended dosing at dose rates greater than 4mg/kg/h).</p><p style="text-align:justify">Prescribers should be alert to these events and consider decreasing the propofol dosage or switching to<br />an alternative anaesthetic at the first sign of occurrence of symptoms. All sedative and therapeutic<br />agents used in the intensive care unit (ICU), including propofol, should be titrated to maintain optimal<br />oxygen delivery and haemodynamic parameters. Patients with raised intra-cranial pressure (ICP)<br />should be given appropriate treatment to support the cerebral perfusion pressure during these treatment<br />modifications. Treating physicians are reminded if possible not to exceed the dosage of 4 mg/kg/h.</p><p style="text-align:justify">Additional precautions<br />Propofol-Lipuro 5 mg/ml contains no antimicrobial preservatives and supports growth of microorganisms.<br />When propofol is to be aspirated, it must be drawn aseptically into a sterile syringe or giving set immediately<br />after opening the ampoule or breaking the vial seal. Administration must commence without<br />delay. Asepsis must be maintained for both propofol and infusion equipment throughout the infusion<br />period. Any infusion fluids added to the propofol line must be administered close to the cannula site.<br />Propofol must not be administered via a microbiological filter.</p><p style="text-align:justify">Propofol and any syringe containing propofol are for single use in an individual patient. In accordance<br />with established guidelines for other lipid emulsions, a single infusion of propofol must not exceed 12<br />hours. At the end of the procedure or at 12 hours, whichever is the sooner, both the reservoir of propofol<br />and the infusion line must be discarded and replaced as appropriate.</p><p style="text-align:justify">This medicinal product contains less than 1 mmol (23 mg) sodium in 20 ml, i.e. essentially &quot;sodium free&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol has been used in association with spinal and epidural anaesthesia and with commonly used<br />premedicants, neuromuscular blocking drugs, inhalational agents and analgesic agents; no pharmacological<br />incompatibility has been encountered. Lower doses of propofol may be required where general<br />anaesthesia or sedation is used as an adjunct to regional anaesthetic techniques.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of propofol during pregnancy has not been established. Propofol should not be given to<br />pregnant woman except when absolutely necessary. Propofol crosses the placenta and can cause neonatal<br />depression. Propofol can however be used during induced abortion.</p><p>Breast-feeding<br />Studies of breast-feeding mothers showed that small quantities of propofol are excreted in human<br />milk. Women should therefore not breastfeed for 24 hours after administration of propofol. Milk produced<br />during this period should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised that performance at skilled tasks, such as driving and operating machinery,<br />may be impaired for some time after use of propofol.</p><p>Propofol induced impairment is not generally detectable beyond 12 hours (please see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Induction and maintenance of anaesthesia or sedation with propofol is generally smooth with minimal evidence of excitation. The most commonly reported ADR are pharmacologically predictable side effects of an anaesthetic/sedative agent, such as hypotension. The nature, severity and incidence of adverse events observed in patients receiving propofol may be related to the condition of the recipients and the operative or therapeutic procedures being undertaken.</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAATYAAAH1CAIAAADzokXkAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAADpnSURBVHhe7ZvRousqjkS75///uafi4lQUgTF2iLed1HpgpEIIkK0k+9zp//7vf//7jzHmqvxf+b/GmEviFjXm0rhFjbk0blFjLs3LPxf997//LdZCmuq4NUylmOSCzQx9mFAMpoqr9u7+5oGNOUb+FuVbOOVd/OgLrXOS1LFrIJLj4JJ3WtqYKby0aHwLacd3tH6noTQDaMSpRIykTYPUrhTaTRgAaCcRUAF0dVm6NKiAWqxdIpu6MXPp/S2K1y5+20QbyKYRg/n2xx6IBiOpyIjUSVKGNZrZYh4S7ZgZOl3aDONIYgyIU9E2ZiIb/1yk17EJ3svBV3MwMoXBjv0Qp8bpXwEo82bkGlh+eK0xfXKL8lXjyBdXQIwK30uJdNMSALFYC4yJohbSoM0p2DTWpigC6QBusRYwVa+C8lj2ajAGSIQtQ3qMJAowZjqNF+6biN1Fw5h7sfFD1xjzt3z5t6gxd8ffosZcGreoMZfGLWrMpXGLGnNp3KLGXBq3qDGXxi1qzKV5/ndR/3+xGXMR4v+3wkuL+v+NYReuGHEd5pLq6R+6xlwat6gxl6bdoviqJcV/mynZmEF53k84l8cNA0X9Pcr9A2XiH7USWZtNejNtREo07sjqt+jmXxfjd0YksoF3ysQkVy40jqfxl1EdZCzyKHvjhRbGDE1RXPl1Es8/TNkDsjEmtwli4ixdLSRSorHMZNJszLOWNuWkQuMR9EmaR6KhY0Q7GRqhpADaGOUK6pdCtxDpXiQqyU6iFFIvpJsWUpQbM0Tq2TrP34LDxJO0v0XTNbSABkYZ9VWTuMYjxb8kUuod+6TtYioa5xO3hg10PJ6WdiQGYFQM4wkVGfdCx44VWLu1oIJRkdEGKUNCy2kIBAPpmpVxNVb/Fl07MXTMFmcBylrwCMqW0q6RwuTqYDL+iroajwJ1S7QZ8JXo1hjXHln/USqDSG6kDhbQ//ad6bD6t2h9Yl4v6rQxRrGG9wfNAkEkxV8BAXWSaGMqGSfDfevd48njrOzm1YB0uTSuT/9G0WaMxERazuDiVLvA4EiWkCcxWDZ0GoBhF+R5Z5xSdk1/9jAqzSeSf5pjNTlz1Tlc+Wx3JNVz9Vs0gjXFMn+B6//LDLUoevpDH5PMDIr/Axy47K+VyESeX6n+qDbmIsRP5JcW9Uf1Llwx4jrMJdVz6IeuMeavcIsac2ncotPA7xNQnMr9Ncbv3ixUU4z0Zw+wlnA5yO7jTWS1RU87wV54sMHjnXmL+u+xn/0LbVfZm1XaLN302q4lPHa8iXz2WzQ+qvqxSamNNVJAdOu147MfgltgFNJp0yBxilC5KXiJeQXeBVCnQQVQBMV/DSO0l8kXNNWEMSKJ0Y06SbOErogibZKmAN3DbLRo2WQFBsSRyIZBYNfPTIrEaIsowtAHGFxmINEmDJbNJSLuPgvl5EgXI+1HxD+iyFFLMNKYfrwz0eF1RymxJilsDS0BMGhHEcAVcDmlkWJNCuPIJDCoENpxJLBTcrqKXJK1dx9h+1s0nSm5iajDlgsDp5QLpEjHSIO2RiGXS0BcyynQVOTSBuk8nwBbFGuBm9b71gqAWKx7ghuBdIvmTSNcEsP6SzBbrPBkQZFeUSqMjz22DgMQU6x1Ysxazs2NOrRbdOT0gkesLwNFYppljYoTMkSxJs6mYLrxzPVscRaSOxFerT5Jc0eJipFyX9IV6EqMLka9CXGMbgxgVWFQAbHOCcbEsXbFZjDHtdOKGCBD4zGeLxOydC48i3N2OYcDd/mm64tjl1pbdU6Jrvwg0tk++89FiSvX5dPg7qA4Pw9LkQqyVOjjJTpnl4k8ewbn/tn+OYYrRlyHuaR6nvot+vXUH89QokgXyKUhotK06yVXpn9azB67zoGFB5ZcBLfoZ4kfh3hF4EqhG9+bqKzZ90KXbdKf7XBg4eG9/hy36DTYSLI/1FHY4kOZ58IKANpRpA1oR5G2kEgjwRhCN+myqQPZyXgELURRxjLzhFNCIg2Spt7BLToZPhU0ktr1B2EFoo2RruwYI5GKRq2SEUnLFR+XY6RLKFKXQV2zS+DzOVKPo2IExRgWqeN34RadDJ4QeDze1wcDt3543wor0LxvKgtpiuT9unWSg3o27thfK1IYrw9gkDJxiJfTvJnr10gVaxYQYrH+fb5KgVsvicqIfQWatyjWPxggPbkEYr0w0tmFa5tpQTNzXAIYkDKsJQRpYYSZaVDZBdbGhS9HPJbxZ6krdkINL/iY1uow96ifvviu/JvB75w2rfUPXTMfvGHTO2putgROq3GEzmGQZDzPCG7RmXz0NSInbDGLiW9qeu+T+z6s6pTaIgkp/tu4Rc180D8T31GQsu1NPtLPcw88EbeomQz7QSNZZp4ukUiD0F3mH0QxkQKElGgsM08DLJON2UXOYX+IW9RMhl9HaeS73hRB6gS4MUZuIon1EozSNVWH0cVIF6MUuX+IW9R8nM5briYhyR0BSwZXIaxYgaZ4KZ53G7ynEa4YqevQfO8R0+8HJjkWE3XZNGjTqKkTNrdQqhOIJwcv1zjzHF+AK0b+tg5x9+94IukW/qFr7gpeZVCcxdX4TbhFzV3BVw1pul+DW9SYS/PyO56GMeZvib8Fvu1P7TNxxYjrMJdUT//QNebSuEWngQ+/RJk4l1lbM0nMJsOciVt0GvxxopHGaah/Ju6LnLzIruZEMEl2k7VZ6c3ZJorvLGlOSVyWPm0aJE6dTK9FdaaRw63FUH//ejHDYM56yQjjkU10NkEdyKUh4izouEnnKEMukEKaIqhdArtu9cFebS4s1kJMUgcT6WsBNYzsx29mWwsYP8Z0Vlt07WFQ12wMW7NFU4ysBWxmJoObDoYdI70oMJgZYxTjyIDoMpiKoKuRMRjTVCQGK74OjmFUCJUkHiAmoREVIDuKYInaiKcdjWXmgWxNyVjkB7BViliBuhoACkmuSDrdN2m3KLLz3HGnaAO5NBDPWxHajCQSE5qlTYNEHWvp0iCc4kge0QvFf4VT8RgSaSxR71KfsEMnAFM6asz5PkwLg2MH7ntgd26hhdoxJtTunAUKIwqDQVss4U+dI5VlvthLVBHrmL3UC2NmjEguF9B9k+2/ReOxYIN0Z44RKYzkKEMBHMXaVAoDUJRKxOQgbh2DawPQTpF7wdo0Rpi8OJUL0sI6A4lhGOvTxoUxmEaMp62TpGAAG9RbHCCmBQfSKkNamzI3qXcv1iFYMZCukNJiNgUc47lN3FKbQZGeTtCE8bUtlDCO0FNkDJCCMcbH2YgC6IoUT7eZhBk24fLijHHOkinU+66dJOlwi1XBMMYrjHacorFMvsApkGZjNqG0dU7lAWm2OUWbRiSlJRClxGzjxH3ByyGOZfxZ9lZs75N780m/SX27tfvurcPVaJ6fxV+7V1wy/fopof+jy3mg7qT4W5ToqY9/nHrfvzrJX9G8L/oHFOdfJ0dlOm5RM5nlHc6vbFNcYy2S+pKpBMggcWqQGB9t9KfcR9J/NnTSdImCIxKXZE+bRoeNFmWKkURkPNJ8K+l9JU1xjc3gtYBdu5C4JC2XuzftZvyuhL0WTf0W3WYrbgaY34EvQP0aSI+GSFMYBVy+2Rg1FW0BhSQXyI36EvUSJjRVG7RpiDT1CF2ArbbcPH+i3aJYxpXKC5fpSLQF42XTAEsC86PULwAVvip8wTRKIcdenpiBxPwyJD4iQoxGsnYkiClJVIiC32H1W1Q7cVeQDkSWmZ5Iw/wg6X0FUem/vvXavWA5kjTzQCzWHlKqfpLmvsd4KVm0aUCJR4kubS7pxBfrG9H1f5xUh7WX4TBMzl2YsN5OMYv2QpxShnEOLEkwQzrGMvNAUyIpT6cONX1cMXJaHdbe5rUDRH38kOORu2imHRH9H13M7Wm+5aA4i6uxz3jkaTz7Fceqr2o6uGLEdZhLqqe/RY25NC/fojSMMX9L/BZ9aVH/XNmFK0Zch7n4h64xd8ItOg18+CXKxLnM2ppJYjYZfbhEFPWVzhTpz27SzN8UN9m1SpFaJeUwqy3KPUiR1okxm/GdAE6N7AgGw06DP0400jgNVWPivsjJi+wqNQ8Qx5o1XWwG9GkuP5bzwKpjdVuj9y3KbWg3N+ufgLOdmDTVcesk47Mnw60xCupALg0RZ0HHTTpHGXKBFNIUQe0S2Hr0AkqM6cPIR9IKBgDZNJbJJ1KWkMYsRRpgzRZxVSLpcmkA2stkIYk0WDQWii5tiIfptai20SiRQKSikSyTLyIVEF0ulwsjKtyRRJswWDaXCE5RPxlegSMNnoSnkhhHBkSXwVQEXY2MwZimIjFY8XVwDKNCqCRxkLhLGpWQNqChABpUaFOP47KuLIRS2zAiUaQRR6AAKYAJAcQUkBIqEmgqiocZ+hbFGA9EoitbYVKiAeoAIpcBoJkqKUCibFCf9kzi1jhJsVboBPAWGGkUdQZMC4NjB+57bPcpZ9484SxYE515pOY6W/OQU64P2i2azpdOwCmISScUNVXHKCBOJbvjgvHZM+G+cYygaFFMLkgL6wwkhmGs34O4MAbTiPG0dZIUDGCDeos+zMC1oM6flFqkQZsGoB1HGjwel0ebs4+ghTo/xloUcYo2xqjTppFgjJa8yTPLSMZZu34HB6pxzpIp1PuunWT8hCffZdd2DH7zhPXyAwnTkt4P3cSbpzcooMYREDkefH14lzNvtOt1RTDOdsE3/Hmma57vyrhixHWYS6rnjm9RY8z5vHyL0jDG/C3xW/SlRf1zZReuGHEd5uIfusbcCbeomQy+BBJl4pVjU2Bztlh/RP94B+i1KHeau98Udh3szPNftmJnwh9pGGUscmZNB50p8M7sCUw/wGqLNt+zzss3El/HSKmNNTo567Wd2Tr4TZAQj2d62puCOrAUMmjTAE37EfoaHBUil1MdGAaKHxISzgK5EqNCog2WqBcFUASyk/EICmEjtFsUWdKHgVLTANEGfDsBdY7xlY0uRpICaNMQnAVydTa42hdEmzBYNg0St54I0gLayr9suIpiZBC6NyXWAYauQwOjZsnjwosoHQaUaADG0KbRGblKS+JIIwbQlQhjiSpoljZFAlc61yYbBmAMiFMj9H7oMldMTVuGSC6BWJ8sRkqRjlGGxogULgFxLacWOS+PIkmHmY6uBpsbxTG6iGkG0/0CeBHekUok6fWt36wDK1lvndL2d0mzzAmaNxIxAHYyBtnxz0WPE1XZeQJOyZbyiPhHcnnJ4qyvSsTZFJxc0JmN9nQ+mvz68PqPcr/WQU8cY9Omm8ZEXFi7zZGGSC6hyGwYKYLa1VjD4BQjI+bZxfME3ID2Rzlto09TX4TPoy4p9U2awdevVV2HS8HjTT9kSjgxf84sZ/odmpyzyzl8013e4fp1mHtCZKOhnLXyDum0O37oTuHiz9J8JXPfOmQjxW8pEzm7Rb8bfZoKKFGs3WK11iaWpS8xSZEdRXN33KKfJX6yonNql+0U7TXSh3Qnm/km3KLTUM/AmNsqexO6V78Jt+h80CFskvf7hEmYsEjmx3CLzqfZV1SKMwyTMGGRFo5lM3fELTof9hVttpYaLLqIUadFW8ECOgNgx9moMADjMmO+h+dD9QPeS12xKTV8P8nJj9JvzlxSPf0tejn8upuIW3QmF+kuN/k34RY15tI8f/X6L4q9oGLFMmYqsRPdosdxxYjrMJdUT//QNebSuEWngQ8/UvxfpVThH0VdKNJWiRQwEvznrJ2wefim2MctOg3+OMG49xl8GaqDRgE3KQmWjjGwN+NPo/NM107Y1A9c5/mrlxWhbUaoKxbfMLqw09P9viKv1SGiOsSCrNkR6hhhrwXQSLNaEtcyW5zFKOKspqINuFDUGTDWSYiUlCSBmBjgb9HPonJrTI/tW6lvTVtEMdlxpM6irQXAiApH6EAB1EkSNUrkwmTTpSEUxhHBjKcSpzDGVIyk3cctOhk8A5Yeo56HGHwq30F9/cgflqK/dWd2/MybkShOvz7ipa0H1xiSKqanArH/hL6szmt1iKzVRDoz1DEMWJsVa/kB14IU0Fmyho6xlrNJcyNlqIn5wctmnWWmxhUj/TpsVul2Zfz0gVN+/9A1HwRvm8YmmwEX5OQPFLeo+SB4m0nxK8r0rb5FT8YtOpP62wBKFGu3WP9Ym60jI5hNAUnZtKP4PnOzCaRNmd/cqE7YpBkzuPZ93KKfJX4/4InWbnzMUVmzm8S0gPHFeSPtYdJ5ZlGnfXOjweV1GEtXnFem19MtOg09NhjTn9Mas/bCyWedmUcSSYwujagA2VEkS+AD2hKjCx4R/0RBd5l/EMVInIpI7IzRjQqJNqC7hGzgFp0PXne+8YPP4BjMz72KdA14Ho06p0QdmwbGFE+bSKcLmtmiCFtuZDOGCkbYilxmHig+jfUq6VIUJkXuJm7R+aD6fADxGYw/kkGYn3sVaWH6Ru/Dc6ZTpWPvYmRtjJlVk3fOXDOY7Xn0Wdf4HVLFmgWMjwGzchlZL4lKbdfxBDoNxUQFY1w4Yu8iLYRbrFfiRjSgaG1zVb2E1EuYqjgLWkua+UXcaG1TMDgFW3lSJKdk00hoLXk50Noa06Su2Kdr+Ln872TeXMuATxdnOn914LSvf+jeiXu94uKm/anxb3GLzuSmLQQ+ffLbVQYHJsX/O9yiZj748ul8/2x+NdUBS77tL7SRmE2mJJmIW9TMp//ls/nVVAdsLmFfTfnSS0n+vGOffyHgKFNu+Du4YqSuw/hrzYWKh5vWxoA0WwcDinEVRRogLVFkWtKEyWVj5MJapAuo7II5i+NvUTMdvWHNMbkI7sfHgKhjpE6SiDEG0yUxOE6lJRqjy+Syl8mX+8KmG5Ul6jhuUfPH8D3mO32A93tgcPd6o85CBr9/NvDcY/CgRrhipK6DXk3og69pfA9pNGFYiql3WQvDOHieSJ1/F9x3HOwVl7hFj+OKkTfrwOWfLuaNHlY6qn/omj/mhP4Ed+nPGreoOQn0ISjOK/ftnxNwi5qTcB8ewy1q5sNvS35tgigS6iKKsqNCAyyTbZf29+EWNR8BPcOvTYxsofgtqimOCqBCm+Mj+h8UaVARtfI1uEXNZOrW6sOuI9GuSbPsWPDF/QncomYy7BwYcUxumiJymUGNF23SXP6t9Aph+rhi5A/r8JWPIF3K36LmluA9BsX5atyi5pbge4YU/3txixpzaZ6/etMvYLPJj/zQMucTO9EtehxXjLgOc0n19A9dYy6NW9RMBl8CokhT+VDaJmfutYZbdBrLO/l8osn9HfgjDSNoVuBwWbiQ+c/hzL3WcItOo36cV3jAf05sSNh000hSAGkGNw1BJRJ1GlEBcmWITZ0ukP0IfV1F4xhu0Q/CZ/N4aP+QTpsGiVOEyk3RFfRdihE2P7YoaoxhScQIakUGgM21pI7ELDPQ5qgYutTh0iByMcZ46VFUDAzNyjiMW3Qmek4c6fIJpecURY5agpEGlZuC8+suYuRGKUYF7DBeqH5knB3J2YyRWBvHcIt+kPRs8KpBAemdqxUAsVh3gyfnyCvrdvGaaSraQEkYFhWN0UhoFUhG3JeKAnSApCsexMzNJCIuoXGM1RqZTdYqRr35zCjGmtNY4xZPZK0O47yf4ZtI1Xg6LtNeDlTsK4v85qWwnIZfP5Lq6R+6J4G66100EbyOpPjmFbfoTOomVGfqLZRCm4aIStOul5jvxi36WeKXA7pLjSo39aGUNdv8Gm7RabCRZH+oo9yrv4ZbdDJsTjSS2tWYd3CLTobNyUYt0gL7tjjGDOMW/QhsVBhs1NiuUhCQ+jYqa7b5NZ4P3i/BXuqKnVDDCz4mvzlzSfX0t6gxl8YtOpMTvkz8ffVruEWNuTTPX73+i2IvqFixjJlK7ES36HFcMeI6zCXV0z90jbk0btFp4MMvUSbOZdbWTBKzyejDJaD4K4zEGOAWnQZ/nGikcRp63Sfui5y8yK5e4gE4dtgM+PMGvsgnyPNXL58HbTNCXbHmQ40VppvCGCCx48a1tMeDMTJeIqhdGoqMC6MRqUUoxQpbyKCNMYZFYiSoXYx1TqJZTcWYZrzCMKZZwADOnkPazt+ik2FxVWI+YBix7jFGAdFlMBVBVyNjMKapSAxWfB0cw6gQKkkcJOakLeJGCoujlnBMroiiRgQzXqtEFDVCSYZGGnWek3GLzic+UT74Dp0AvhwYaRR1BkwLg2MH7jt393Hqi/PktT4CVhWrojMF+rOfxi06DT7IOEb4bhWnckFaWGcgMQxj/abGhTGYRoynrZOkYAAb1Fv0YYbmiFTcjqNE2WlsTiWaATCwtrZBM1409bj8fFZvYjY5ULFzlkyh3nftJCef8K8Kchrpgv4WPQ+UXuMIiBwP/gV+syDPfsXlv/vDaTquGHEd5pLq6W9RYy7Ny7coDWPM3xK/RV9a1D9XduGKEddhLv6ha8ydcIsac2ncojPh3/McfxZcXxTplc7UGnFJcy3FJeo5G+37stqivC0p0goM2Awju4LBeOSfg6PiT4gbHfhD8O8ojGvVYMAu4pLO8gOZr0/vWxQXJsVvNUxfSbMdt84DxlNdh1gxHRJGB8XIIHRvCq+AUtAgmlKAFEG3qUuhQQXAVs0j3L04t2X0h+6jMP9KE4ES30gqNEA9FRVWkERbMF42DUJ9yXRR4iFhpDG6j/u0guneFJyfV8BIF+Pjnq9KBIpEhFGhWxuAMV/Pjr9FY5loS0l1T7MkBYPm01pmeiLR2gvyI6/OLprPi88xTiV3jZGYr+GlOvHacGlQlAuSAjfOJvrB0aW9GY+RCu0/RKcV6WAKiFfo0Az+82tukuoQzw+9c3fNxrD+khrGY4Qdk9DQ1I1IZ346d7zM3+KKkXfqMKuGzTw3fUDp2P6PLuZvwIsIimPWcYvOpH7n0otYu8VqrU0sS19ikiI7ipcFXxSk+O/RzDMr+d/iFv0s8S1B59Qu2ynaa6QXrpPNfBNu0WmoZ2DMbZW9Cd2r34RbdD7oEDbJ+33CJExYJPNjuEXn0+wrKsUZhkmYsEgLx7KZO+IWnQ/7ijZbSw0WXcSo06KtYAGdAbDjbFQYgHGZMd/D86H6Ae+lrtiUGr6f5ORH6TdnLqme/ha9HH7dTcQtOpOLdJeb/JtwixpzaZ6/ev0XxV5QsWIZM5XYiW7R47hixHWYS6qnf+gac2ncotPAhx8oTuX+Drw4KdK51ThzrxNwi06j/rH3mz//eGuMQK1C8RzO3OsE3KIfhC/o8plekE6bBolThMrdKZdpXRBQSVNyowik064VQjuKtAUVTl0ft+hM9L3BkS4/1NNHexQ5aglGGjd6jWpweBAvSKLCO3JMIgzQzAAYEyNla0kUqWhUJMbr4xb9IOkl4MsB+K6IWgEQi3VPcKP6UuPUNYH7qF2rVgB6sQJNkbxztpN5Xnjt8maNzusCvX4/JMaa01jjFk8k1UGX2nvNfhhiGBDTpoXNPFrYRNmug+5Fnk6aMJscqNhXFvm0S/3IK5qu6R+6J4G6g+KYnfxy9dyiJ4HPRVJ8s4dSu5+snlt0JvUnffr4r91i/WNtVna9xHw3btHPEj/40V21m/pQypptfg236DTYSLI/1FHu1V/DLToZNicaSe1qzDu4RSfD5mSjFmmBfVscY4Zxi34ENioMNqraNboISH0blTXb/BrPB++XYC91xU6o4QUfk9+cuaR6+lvUmEvjFp3JCV8m/r76Ndyixlya569e/0WxF1SsWMZMJXaiW/Q4rhhxHeaS6ukfusZcGrfoNPDhlygT5zJrayaJ2WRswsi1+EfG/TkjMUNNfxY0ZyUuqx+2lEG0kDaN93GLToM/TjTSOA29ExP3RU5eZNcLx1WdJZgt1tHTdlZx9+Ks8H5Ak7jqWIYmz/uM3M1E6oo138tYYbopjAESO25cS3s8GCPjJYLapaHIuDAakSTWMVQwFn9BCg0tkSi3XptgcB1TL5RCgwtBtIHcpIO0nK6U2sAIWwrGTbSK+Ft0MiyuSgyDjyfWPcYoILoMpiLoamQMxjQVicGKr4NjGBVCJYnHQBLtWBuAuzAs6kBrNRXHSJqNC5NCuOk46Xgxf8wsA0DnVBR34RadT3pCxVqhE8BH+3jC4fFPgWlhcOzAfY/tri36y+sAnWpzLUAAwkYiI3vjI4PbpRi4xdrJM8vIriay9gwgpufBMIqx4DRAvYRIb64CUaetgGbOFK+RIkm6lgDqxflHLaaFdHdxYC2XHNtLV2ievD4Ml9AmtVKjPH2QJ0Y+nTRhNjlQsXOWTKHed+0kf3VCMeUAa/c9/3ZpR//QPQ+UXuMIiBwP/k1OKNHJ/Vnz7Fdc9c9Pcy9cMeI6zCXV09+i5iPgPQOyk9JHYXGJDMFZQYVT34Rb1MwHrYLvAX0V0JC7i/6qxx4Lxf9G3KJmMvpCSwahW1Om/7U3bRiaijaIYbJTzHfgFjWTUbdgjI1E4mx0v6+1ZuEWNR+hbs4O7s8OblEzGfUbDY0y4nemjJrHgoE+H4m5Nc/rff1Vp+OKkel1aCaEiDHqddh3PJF0C3+LmtvwBe13ALeouRzNVqzFEeULcIsac2mev3r5W98Y8+fEnwMvLfqVvxM+hytGXIe5+J+LjLkTbtGZ8I8Fjj8Lrp8oE+8xkocxy54lWMZ9WW3Rw5ccjGfYruCLg0Pi98ktjvpR+CMNo4xF7jFStJE8gE+hOF/BxrdovLDqGAvaKe74VD9hZ7YO/nNQrmbFOihGBqF7U3QFXYQKkRJHGrLBmluLAHYsPoEbY+5Ir0V5Zxq8Jw1em6gEHMky84wnaUqlhFsnjDBYNg2i3S9IPB6MNEb3cZNWMN2bgvPzIhEqGJcblysrjC4NuQygAuhyVAynhGa/g9G/RVUREAu0TD5JUxppENkMBnXCRX5RQBTJNR8GTlUsszwsFGTkSa3VbU3/EZ6FS0WMbl0j1r04W6S0NFKG2sXYCcZIhfafgAOk3dORFBAP36EZ/IcXHCTVYe2y8Xay6ytDSRmiQnstJkXSoE77FqQDP53b3eTPccXIZh1iwEeLVie/4zNKZ/Z/dDEfBG8bKM7iajSDuEXNB8G3AWm606kzf26v03CLzqT+fnh8ibx+jSS3WAPfLcvSl5ikyI6iuTtu0c8SP8XRObXLdor2GukLoZPNfBNu0WmoZ2DMbZW9Cd2r34RbdD7oEDbJ+33CJExYJPNjuEXn0+wrKsUZhkmYsEgLx7KZO+IWnQ/7ijZbSw0WXcSo06KtYAGdAbDjbFQYgHGZMd/D86H6Ae+lrtiUGr6f5ORH6TdnLqme/ha9HH7dTcQtOpOLdJeb/JtwixpzaZ6/ev0XxV5QsWIZM5XYiW7R47hixHWYS6qnf+gac2ncotPAh1+iTPwe5f7/KOoAI/HjCdeyRT3aoHaL9WqfiVt0GvxxglHGIv80e4swEj+ecy0y6imm6bI517J9Grfop3h8Gi9El0ZURFOhKIPQvTJ8m/VO88w8PJEeoQhk1+Ij7p+xyAWJJIqEOih+a7Y4/6YoAtmaOhO36KfQa8qnC4M2xxigsFqhiDHpMG4Ez8zzy6URR92LNpBIm1PRjcQY2CkmTkmRDeopLdGYcp6DW/Q84gth9pKqF90pnTP4dM5/iM+7TbnnT9GsGB8h9OazpM5VzYAmzfh6679CNxKbV+tUAFNK2DQeQdX1m6lEXAu7Exy3a4alfT8Bdy8OXDlpwmziipG71OGm5/QPXfMT4L3XeC/couYnwPcSKf59cIvOpP6QhhLF2i3Wut3kkeU1Jipxas02d8Et+lnixzY6pHbZNmv2GjEP4JJoj6cyF8ctOg31CYwPdcWbmd2ud8QtOh90ApthYj8wGzMXyfwGbtH5NNuJSnH2w2zMXKR/vJnZXBy36HzYTrTZUeqr6CJG3bVmM1JAjHqclYIAjnCjbW7K8/n5We6lrtj0Gs5N+KFH7DdnLqme/ha9NH71jVt0JhfvKDf8HXl+peLrlYYx5m+JH6YvLepP2V24YsR1mIv/FjXmTrhFjbk0btGZ8O95jr8MKkCKP8Cu4Dfpn23kJHXMkvLIwk1WW5RbkiKtMxKzi2MJD6yaeHKkwp8Q00vxI3T+mp1e0v5fziN/V9cxm6t4i5Hkid63KNMpKfcYrJfCaqNPM2xTTAF9V6zpYjOgBuVKFaPRQTEyCN07wgpgLDdZ7qKRPOIqEUQ3BmCMLkk2XRm1SKLeh2Gg+ItSrH8oIE3JTbNypQC6TXotipWstbJQkU0eocElVOJUfGBAOmMimuUI0lqiWcBzxvjoyiBRT5EJTh0Dy3ls2NwljtFdtmoE0701ugtdXpPK487BXeaLHmNSAFgLgE0X4xJYRNrR4BKgtWsjV2nJWkwzgGJUOFLHGHW6TTa+RbUSNtEGdDFFWzE0OMYpjAR2dCNr8cUKa+uxuRbUkSSFgRQDAyAtoDLI3vhfADVRYSOpVv3SrSVZg9n2rqrha3AsSf9GIzw3joeQTSNtQyWO0jGm4IiW0I1JpNCQXiuwJXZoRjbT0pAeZ4ECahhcnAUuTDlpUOnTDO4c4CKs1SGCgGYRBuuj/HVxmnthlB5j6qno9mEw6MfH7Uhzl76ovcDTSRN9mHo8vkbb7dr3Utz35HP5kzqcuSn3Om3HtNHx/+jyznHjIc65tvkm8P5oPAG8oqf1Z83BFn3zuG5L8w54f0jxP8+ZeyWOf4uamvpzHUoUa7dYA98Jy9KXmKTIjqK5Oxstyoe9+cj7AfXsYFoxHnk14qcvblG7KoXsNdIHeSeb+SZ6LVo/bym1UbM2lfToNpdIrGeb8X8FDsOegTH3YHsTule/iXaL6p3Q57QUGvVLQB3IprFMFqTHtExFoi0UKUPUx7gCOJUuUqSjMAkTFsn8GKvfonon+IpIebwsy/uXRgUQKZolsqmDteVJlCIbpOQXAafiweLZjh2VSZiwSAvHspk7stqi8Z2grZEGkUhXRL2OJ7BrN715CuAsbZLc67C0VbkFD6mjRhcxMBgZbQUL6AyAHWejwgCMy4z5Hp4P1Q94L3XFptTw/SQnP0q/OXNJ9dz4F11zPn7dTcQtOpOLdJeb/Jt4fqXi65WGMeZviR+yLy3qT99duGLEdZiL/xY15k64RY25NG7RmfDveY4/C66vOhDqszicM64aybDssxo2kmEKqy3K84mi7mHvqn58Pfs41vAW45GHwRb4E+KEjS6O/o6iMf3P1MMJuZAPaCRJP2b6vdbofYviEIKK3r/aEGvvaGft2hKwmQ2s2aIT0Ix/h7VydVCMDEL3psTz017uVEjiI+h1CaGyhDyIotCUDNkiKs1ZUvyQREYfhoHiV5TpQ2z/0C2bLMjFW0g3BYDmVHRlx0iyzD+QTWOZLEhnJ8BmHhJtwWDZNEh9hlnE5DDSGN3HOVrBdG9KOj8vCIOjXCqKrK8cF8KWK6KrVFoiMSlpFkaKiRtFnUZUMNYZZCiAwN3L0N+iaT+AzTRKVAyIU8mVEZOkeCJFs4Q2RbC2ti+SlHkKyFksEx59QlWiUYetLfwQ778Maxl4Qej11AjPjCk78xLo0SVR5MLoNm0hsZ6lsrYKY62DGK8MsJNIG8RZ2gfQLiIlVEDcukMz+PDxTiPVQeeHyKmkyMbYmQJSmqQwZkhp96KcIJ1nMOdacMzcR7cgTydNmE1cMfIddeAt3rnL+xlIyuD/6GLMg/e7a0p/1rhFZ4InVKx/QIli7RartTaxLH2JSYrsKN6d5YonXef97pren8At+lniM8OrVrt8/6K9Rnr8nWzfRLr1D+IWnYZ6BsbcVtmb8M97VQfWMaJCQzaIbq0D2cl4BIWwr8QtOh90CJvk/beHSZiwSJdHB6aBESIMzoKmSKhoZFiyYQCtjVNfiVt0PnqH9BoBKsUZhkmYsEgLx7KdSTpwJE3pgps3ijGwk/GtuEXng9covUnpfeKIGBiMjLaCBXQGwI6zUWEAxmXmj1k7EnVBN4mCa1OMjIvc9ASeFWRFaJsR6opNqeH7SU5+lJ848MlXuBTp7v4WvRw/9WridQTF+QeVWv9N3KIzuUh33ajJcVRS/IUi/dJHVQe3qDGX5vmrF78r/Lm1C/8SMx8idqJb9DiuGHEd5pLq6R+6xlwat6iZjH//z8UtOg28mvHtTO7vgB9pvDso0hukJFNy3gu36DTqv8d+8y80dhHuDt7pKOVpur+DW/SD8K3CKKTTpkHiFKFyd3gR3ghIrNFUHDvuj+AWnYm+NzjS5Qd/+viPIkctwUjj1i8iDg90Nd1UOqGoKRiAARSpRFezP4Jb9IPonSN4saDUb1itAIjFuie4EWhejaQL0u3ER+5enF08KzJYHSPWKka9fo0kxprTWOMWT6SuQ7zm5h0jKlEi6bcoy2FSPZ9OmjCbHKjYVxY5v1J+kd4jFdA/dE8CdQfFMWYYt+hM6iZUZ+JzkR+NUmjTEFFp2vUS8924RT9L/MWC7lKjyk19KGXNvj66oJmCW3QabCTZH+qoG/WqmYJbdDJsTjSS2tWYd3CLTobNyUYt0gL7tjjGDOMW/QhsVBhs1NiuUhCQ+jYqa7b5NZ4P3i/BXuqKnVDDCz4mvzlzSfX0t6gxl8YtOpMTvkz8ffVruEWNuTTPX734BUzDGPO3xN9KLy3qH1G7cMWI6zAX/3ORMXfCLToNfPglysS5zNqaSWI2GX24JFImPsbaLhJjgIy7sNqi8SaHb1UnieM4u1btTT4L/jjRSOM0dOuJ+yInL7KrpDwAF8rt8P7z2twCjMRck+1vUT4n2TQiEmsDNJeI/ixJMf3k47MfgltgFNSBXBoizoKOm3SOMuQCKaQpgtolsOt3GkqM6bPke+aXAZb5hxtHGrJFmgV0SZEW5HIK6Arx5LtucQV6Lbpc8+Xa0RZU4hSrQGOtIgyQQaIebSSRwoQk2oTBsrlErB1mIjwqRxrckbtLjCMDostgKoKuRsZgTFORGKz4OjiGUSFUkjgI1gLZSEKXNnWJQLrCkkhDSzhSrOHsd9BrUdwzXpUuawQkcky1S3A2jhDTSCMhUfs2N2oqcmkDrf0ocQvsWKwVOgE8LUYaRZ0B08Lg2IH7vrl7vcveGykDT66RIqFY63en3aK6Z7zwcv1SKelU0gg0G+3OGNGOIM7Crt3BYJDc6TB/HCM4ZxSTC9LCOgOJYRjj9UlcGINpxHjaOkkKBrBBvUUfZuBaKhGISJg2pYtRShwjUmIGGctMhgFMfkeeRx+8BsIwfujC9yrlgdOes2QK9b5rJxk/4ft3YYbBkzTD3j/Dp0kn3P7nopoP3fD6tXsTXFDjCIgcD74+vMubN8Ibggz1e/Ko1BfVKvK8bfPmpoMrRlyHuaR6HvkWNcachlvUmEvjFjXm0rhFjbk0blFjLo1b1JhL4xY15tK4RY25NG5RYy6NW9SYS+MWNebSuEWNuTRuUWMujVvUmEvz8j9Go2GM+Vvi/xjtpUX9v/rbhStGXIe5+H8vasydcItOAx9+iTJxLrO2ZpKYTUYfLgHRpS2SmNxddNY2dYrLopcDFOsfVJaoMiXjZNyi0+CPE400TkMv0MR9kZMX2fV28gBaRTeRxGbMIJ21/Skwcq9OknPotagusOsJkbUlTX0k/+AZDhx1LjwARkEdyKUh4izouEnnKEMukEKaIqhdArt+NQffaZIycGFaLrdp1KQpukSupqKxzDyArVNFO11NU1FPMaex2qKbp0lXKlaFppoxSayDm6vASDawmSeyK3gNPVq5zIYxinFkQHQZTEXQ1cgYjGkqEoMVXwfHMCqEShKPoeQxm/LzADQwciqNCUXWxFVKXtPJcCnaLaqLwdA1aGjkDYluy5EsM8+wFLNoObg4C1I6Ookijy0l7S4UAGTHVY8UR4nLmbZDJ4AneRzo7SMlmBYGxw7c98Du2iLyzi2YEDSTaBY2R5Hc27H9t2inIpyqA+opxsuWQZ0KXRhpOUYpRHZTFJthyabLETuCZWYUxscxgrRRTC5IC+sMJIZh5GkjcWEMphHjaeskKRjABvUWfZiBC5cEOTlHzmKkAYVTcGk0R8IldSSJutwEZkFzSozEnMDzBPE0sGlAkS5RcLY468QwJVxb2J/CGGfrbIwBdZIYXI8l6B8Qi7UO1xZnjHOWTKHed+0kp52wv9HgMZphEDFGvQ4bzP8+aaOnc9oJvoa9FUM8jcFVe+PnUt9u7b5763CAfil2Fap52locUT5E2ujpnHaCr8EVI67DXFI9/d9Fjbk02y2Kni7WOiMxa2Dt+PJ3NjLmjhz576JxKoXJbS6vxbVUm8tTQDPemC9g9IcuekAUqQJT+A3NGBoUOdIQUvizG7bWgmgLBsumQbSdMV9Gu0X50kdDwJWi3qAimwZjBPXiLNCNS6hwJMtMTyRaa8yXsf1DVwZ7AK4UQDuOtaGRhpCbpuimlqsDivM6ZcyX8ewEvOj+ItqFK0Zch7mkeo7+LWqM+RPcosZcGreoMZfm5W9RGsaYvyX+LfrSov6jfxeuGHEd5uJ/LjLmTrhFp4EPP1Ccyv0deHFBhVNrKHIve1f1NxrJFjPQJlQ6jMQ0WW1RbkyK1GUwDPQjx/PUcO2sk+yl/rH3mz//eGuMBEXGyKk1NgNq+Ox2LeRJOks2s6UMNOT2GQyr6X2LphM0X+imCPbqfUZWpZjoNpdLrGeb8QdgHoxCOm0aJE4RKl8A76IbLZd7UYSUJaSBZhUjVwqgC2TT0LiJwh6LF5piRDpjSHJJCqO7Rq9FsZj9qUQ0QBIxiqiLqCtnHAns5CaDRD3a8dMENnUQbaFIGYLx1HehhRzpYqT9iPhHFDlqCUYax85wTVQHGrwdRwaAqMBojvVscxXd5tTamFytokFbhkSxtheJCsMYL7HDxrcot6TNXByJFO1HYmStN8EUaJ47KhhpJCQyA1hLlUQpskG6zmGQp1gLzFwnrxUAsVjfQrzRgds1q/RpDj8FPmsYaxkYMHKjdovWi6GA4vyDShxJrZCkNMPWVtV6PGGchV279XVkyCbJ3UtdeiZsppWoGCn3Jd4FUASqCcVYKIVJAQygSKXp0oh5NNZbcAQpOcbkYkxIhNHMKV3QrffSOMIzab3BZbnIUQ8c40ZFHucrL/VpWLRm6ZLY+6F7TW76QuDYoDjm51nrz5r7tegd+xPg2KT45ucZfBnu16JXpv6eXL47nyJdIJeGiErTrpfcC5x/7xU6SzpToJ7qBNfsCv4cbtHPEj8p8ciX79Gi0I3vQVTW7Luj64/TWdLPVs8mZa2k1A8c9RO4RafBRpLNxzwdbPGhzLPg3SMUOSukLCEPkguk0BD11CM60FFoxJE0dblSAN3TcItOhk8RjaR2/TV4cV0fBguCkQqIiuLhUl9CGkokTdHQqKlaqac0gjRLF6MUuafhFp0MHiGfYnqQcKEXx6zA0rFQqYDi/Uo2M1/2AT2PddkjXpZUsWYB49vAWSlw6yVRGbGvQPMWxVrArGLiVK0QxjdtGvWSXTTzxI0SjE+zSjIdbBSTX/fBX5+6YifU8IKPaWIduPCCdzyTdH3/0DWTwRumcS/uzxq36ExOeLeu//rihKT4Ozm88FtxixpzaZ4/KvwDYy/HfssZs0nsRLfocVwx4jrMJdXTP3SNuTRu0Wngwy9RJs5l1tZMErPJ6MMloPhd6sik0AXFX4cxMVjGrXGLToM/TjTSOA29jhP3RU5eZNe7zgMMrmKw0I7FP1TJvfEX5/mrl9WhbUaoK9Z8KWOF6aYwBkjsuHEt7fFgjIyXCGqXhiLjwmhEahEKRi2hTYM2Rq2KxmN6YW1tEwZwCViz70I6s79FJ8PiqsQw+HrFuscYBUSXwVQEXY2MwZimIjFY8XVwDKNCqCTxAMxT75IyKwAjp2iTOJvG9094Zdyi8+GrQzbfnk4Apvj+0SjqDPRac+zAfQ/sri1AvUvnRp2pJptXuDtu0WnwXYljJL6yILkgLawzkBiGsX6b48IYTCPG09ZJUjCADeot+jADF9Im0mt3bUoGx85RCRSw98AX53mf77vbpzlQsXOWTKHed+0kf3XCxPiBL046tr9FzwOl1zgCIseDzbfy7Fe8DXf8yPlDXDHiOswl1dPfosZcGreoMZfGLWrMpXGLGnNpXv65iIYx5m+J/1z00qL+d7lduGLEdZiL/0XXmDvhFjXm0rhFp4HfJ6A4lftr7L1+io9u1EHtRoUukEuDJPcWrLbocs1CkfawuepY2ll8Yvf677Gf/QsN5d179xQf3c4UqN2oyOYTj1N3ofctyvukS64RZ9ciqXfy9JNIqY01mgGbq2bBjTAK6bRpkDhFqNwUnB9vji5Co4ZTy4oXJC5RzzC6Ygl5QDuKtAFtKckFsK9Mr0VxevZnvAntGj0PgDC6jNcqdbugHg0CO2YgUiTGWcJZIJdGBGJ9kimkW9PlXmnHKHJMB4NB5Y7oFoAXifeiLQWkm6b4qKRRC2lTJ7XNkWExoZJck41v0VgCujSiSIMKiHaEeipQBIpEGClGinSMMjRGmrN12OfAUYu1gK2h6PyiVgDEYt0Q3ohX6F+kefcmty7IO7RbtC4cFNVobZYiDIqAtsbkYgRKtcwXUQZBTFRoP6JfwxIKo0v6S96HR431aR6DSFSMlLuDi6Qi0OUF4wOlEUfNYqRBkcrIWOdPRtxC4zV51pHnpr0Gb7IZNpGRU/0VB8525esc5isv9YekevZ+6DY582F807PHXUBxjBlmX4ue3DDf9NmMu5DiGzPG7m9R06H+nkxfnnSBXBoiKk27XmK+m9UW9aswhfi1iZLGL1K6sc5RWbPNr9H7Fm2+E1HUCxTdnwXXj+33oWq4V3+NdoviJcCrwLchoQDaGP3SRJbClOoVyZg3GPpbVC+cDNoc+UZy5NQvgyKwGqBIC66POUbvb9H6raIoWyOJ9o+z9OmjdGtVwogAjtRBVNZs82s8H7xfgr3UFTuhhhd8TH5z5pLqOfRD1xjzV7hFZ3LCl4m/r36N51cqvl5pGGP+lvhB/NKi/oTehStGXIe5+G9RY+6EW9SYS+MWnQZ+n4DiVO7vwIuD4ncZiRxMFamXLPts59mMUUCMHMl8mNUWxa6Rou6kXkhlPOHhrUU/Q3O2FkeOUf899pt/ofHWg3cfCTtQxnrJZhI+4gN7fZretyiOK6i8+UInPbqbmTtryWYG0sk5HebHKKTXdlJEU6EYpyhekHg2HTWKgrOAdhIJRUKXOqAIiv8PiTISmk2uFCCXvSCFQEzKRLZ/6D4O+I/oyk4xgApGIT12Oy9Goi0YL5sGiUWhEgOiGHekQgPArvddYl9ixtGpONLlAXQMQpezgIZWxTFloEIxTsGGcTV0TtlAUzQEpzAqPopxCjAbxzQlhSN0hUWdY3IxMhhj1OkmmuJ0hv4W1UFlLPKDKMrgGOsCZFMHCuBIlpmeSNaSN0VBJY4kKvWpqGAEVAZJ8UqizCSFfTfNCtRsBsziWPF5vHMO2WtRVrM4lUtqkW4cSbJrt/PiMqA4r1OkVsBaWBybNBfieCOPBDEMLv7WdtTjqhi/NtLgKoma+lt0GBmqBpV4bBmP6QXYawFxZEyzAvWY3LRKxGDESGkGn8ZL+WSbEQ5U7CuLPPFS169P84Rzj52yDf3QNe+DuoPimBasj6uUcIueBD4XSfFNRSnQtUvUPN5Hz+wWnUn9DfD46gxi7RbL3x5mhQktuuvdev9FZIa7vNzx8xXnrN0rH95cgdUW1atTv0NrU523bS2yk6GZrRMPRpZ8DmzEDoRxYFO3q2nSblG8K+mNebx0/6BLnVDnElHmWtnAEpLzx1c8ZSOYZUyCs/UBMNZbfxrsqJMUyZijtFuUb5hGiXFMARxJtEEKjktokE1bxlo2zgLZMeA0sCM3jfuefwzzHax+ixbr1QZ0myNovoUMILQ10iDRpZ2yaRbQTiPoLDkNnEHH4AF0jOgiBoYijWnyfEX8uuylrtg7Nbxv/f3mzCXVc8K/6BpjPodbdCbvfJn4i8g0+M9//h9IT5nlrqraZQAAAABJRU5ErkJggg==" alt="" width="310" height="501" vspace="0" hspace="0" border="0" style="width:310px;height:501px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><img src="data:image/png;base64,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" alt="" width="324" height="264" vspace="0" hspace="0" border="0" style="width:324px;height:264px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Reporting of side effects</p><p>National Pharmacovigilance &amp; Drug Safety Center (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p>By reporting side effects you can help provide more information on<br />the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Accidental overdose is likely to cause cardiorespiratory depression. Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression may require lowering the patient&#39;s head and, if severe, use of plasma expanders and pressor agents.201216-15064</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: other general anaesthetics, ATC-code N01AX10.</p><p>Mechanism of action, pharmacodynamic effect<br />After intravenous injection of Propofol-Lipuro 5 mg/ml, onset of the hypnotic effect occurs rapidly.<br />Depending on the rate of injection, the time to induction of anaesthesia is between 30 and 40 seconds.<br />The duration of action after a single bolus administration is short due to the rapid metabolism and excretion (4 � 6 minutes).</p><p>With the recommended dosage schedule, a clinically relevant accumulation of propofol after repeated<br />bolus injection has not been observed.</p><p>Patients recover consciousness rapidly.</p><p>Bradycardia and hypotension occasionally occur during induction of anaesthesia probably due to a<br />lack of vagolytic activity. The cardio-circulatory situation usually normalises during maintenance of<br />anaesthesia.</p><p>The rationale for developement of Propofol-Lipuro 5 mg/ml was the reduction of pain at injection<br />site; this was clearly demonstrated in two clinical studies, one in children and one in adults.</p><p>The formulation of propofol in a mixed medium- and long-chain triglyceride emulsion leads to lower<br />concentrations of free propofol in the aqueous phase compared to pure long-chain triglyceride emulsions.<br />This difference may explain the reduced pain frequency and intensity observed with Propofol-<br />Lipuro formulations in comparative clinical studies, especially with Propofol-Lipuro 5 mg/ml due to<br />the very low concentration of free propofol.</p><p>Paediatric population</p><p>Limited studies on the duration of propofol based anaesthesia in children indicate safety and efficacy<br />is unchanged up to duration of 4 hours. Literature evidence of use in children documents use for prolonged<br />procedures without changes in safety or efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Distribution</p><p>After intravenous administration about 98 % of propofol is bound to plasma protein.<br />After intravenous bolus administration the initial blood level of propofol declines rapidly due to rapid<br />distribution into different compartments (a-phase). The distribution half-life has been calculated as 2 - 4 minutes.</p><p>During elimination the decline of blood levels is slower. The elimination half-life during the B-phase<br />is in the range of 30 to 60 minutes. Subsequently a third deep compartment becomes apparent, representing<br />the re-distribution of propofol from weakly perfused tissue.</p><p>The central volume of distribution is in the range of 0.2 -&nbsp;&nbsp;0.79 l/kg body weight, the steady-state volume<br />of distribution in the range of 1.8 -&nbsp;&nbsp;5.3 l/kg body weight.</p><p>Biotransformation<br />Propofol is mainly metabolized in the liver to form glucuronides of propofol and glucuronides and<br />sulphate conjugates of its corresponding quinol. All metabolites are inactive.</p><p>Elimination<br />Propofol is rapidly cleared from the body (total clearance approx. 2 l/min). Clearance occurs by metabolism,<br />mainly in the liver, where it is blood flow dependent. Clearance is higher in children compared<br />with adults. About 88 % of an administered dose is excreted in the form of metabolites in urine.<br />Only 0.3 % is excreted unchanged in urine.</p><p>Paediatric population<br />After a single dose of 3 mg/kg intravenously, propofol clearance/kg body weight increased with age as<br />follows: Median clearance was considerably lower in neonates &lt; 1 month old (n = 25) (20 ml/kg/min)<br />compared to older children (n = 36, age range 4 months -&nbsp;7 years). Additionally inter-individual variability<br />was considerable in neonates (range 3.7 - 78 ml/kg/min). Due to this limited trial data that indicates<br />a large variability, no dose recommendations can be given for this age group.</p><p>Median propofol clearance in older aged children after a single 3 mg/kg bolus was 37.5 ml/min/kg (4 - 24 months) (n=8), 38.7 ml/min/kg (11 -&nbsp;43 months) (n=6), 48 ml/min/kg (1 -&nbsp;3 years)(n = 12),<br />28.2 ml/min/kg (4 - 7 years)(n = 10) as compared with 23.6 ml/min/kg in adults (n=6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no specific hazard for humans based on conventional studies on repeated dose<br />toxicity or genotoxicity. Carcinogenicity studies have not been conducted.</p><p>Reproductive toxicity studies have shown effects related to pharmacodynamic properties of propofol<br />only at high doses. Teratogenic effects have not been observed.</p><p>In local tolerance studies, intramuscular injection resulted in tissue damage around the injection site.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Soya-bean oil, refined,<br />medium-chain triglycerides,<br />glycerol,<br />egg lecithin,<br />sodium oleate,<br />water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other products except those mentioned in section section 6.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After first opening: to be used immediately.
After dilution according to directions: administration of dilutions must commence immediately after
preparation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&nbsp;<sup>o</sup>C.<br />Do not freeze.<br />Keep the ampoules in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is supplied in glass ampoules of 20 ml<br />Glass ampoules are made of colourless glass (type I) according to Pharm. Eur..</p><p>Pack sizes:<br />Glass ampoules: 5 x 20 mlction 6.2.m</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Containers should be shaken before use.</p><p>For single use only. Any portion of contents remaining after use must be discarded.</p><p>If two layers can be seen after shaking the product should not be used.</p><p>Propofol-Lipuro 5 mg/ml should only be mixed with the following products: glucose 50 mg/ml (5 %<br />w/v)solution, sodium chloride 9 mg/ml (0.9 % w/v) solution and preservative-free lidocaine injection<br />10 mg/ml (1 %) (refer to section 4.2, subsection �Infusion of diluted Propofol-Lipuro 5 mg/ml�)</p><p>Co-administration of Propofol-Lipuro 5 mg/ml together with glucose 50 mg/ml (5% w/v) solution or<br />sodium chloride 9 mg/ml (0.9 % w/v) solution via a Y-connector close to the injection site is possible.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                B. Braun Melsungen AG
Carl-Braun-Str 1
34212 Melsungen
Germany
Postal address
B. Braun Melsungen AG
34209 Melsungen
Germany
Phone: +49-5661-71-0
Fax: -+49-5661-71-4567
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>